MedPath

The effect of Theobromine supplementation on anthropometric indices, glycemic indices, cardiovascular risk factors, and genes expression of PPARa and Sirt1 in subjects with metabolic syndrome.

Phase 3
Conditions
Metabolic syndrome.
Registration Number
IRCT20091114002709N59
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Overweight or obese (25 =BMI= 35 kg/m^2) men and women aged 40 to 55 years .
Having metabolic syndrome according to IDF definition ( Waist circumference greater than 94 cm for men and 80 cm for women, Triglyceride = 150mg/dl, HDL-c = 40mg/dl for men and HDL-c = 50mg/dl for women or medication, Systolic blood pressure = 130mmHg and DBP= 85 mmHg or medication, Fasting blood sugar= 100mg/dl or medication)
Tendency to participate in the study

Exclusion Criteria

Smoking
Subjects with diabetes, cancer, hepatitis, cardiovascular diseases, hematological disorders, Neurological disorders, renal disorders, gastrointestinal and thyroid disorders
Insulin therapy, use hypoglycemic and weight reduction medication, vasodilators, hormone therapy, corticosteroids, non steroid anti inflammatory drugs, antihistamines, Selective serotonin reuptake inhibitors, anti gout and psychotics medication.
Use of any vitamin and mineral supplement, antioxidants and omega3.
Pregnancy, lactation and adherence to a specific diet
People treated with statins and antihypertensive drugs will only be included in the study if they are treated for more than 3 months for statins and more than 6 months for high blood pressure.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath